Moreover, CRBN expression levels may serve as a predictive biomarker for the efficacy of GSPT1 MGDs, providing a basis for precise cancer cell-targeting strategies in GSPT1 MGD-based therapeutics. This evidence concerns the gene CRBN and cancer.